Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jaguar Health (NASDAQ:JAGX) has announced the granting of restricted stock units (RSUs) to three new employees, effective January 8, 2025. The company issued 15,000 RSUs each to two employees and 45,000 RSUs to a third employee. For the first two employees, the RSUs will vest over one year from their respective hire dates, while the third employee's RSUs will vest equally over three years, with one-third vesting annually. These grants were approved by Jaguar's Compensation Committee as inducement material for employment acceptance and require continued service with the company through applicable vesting dates.
Jaguar Health (NASDAQ:JAGX) ha annunciato la concessione di unità di azioni limitate (RSU) a tre nuovi dipendenti, con effetto dal 8 gennaio 2025. L'azienda ha emesso 15.000 RSU ciascuna a due dipendenti e 45.000 RSU a un terzo dipendente. Per i primi due dipendenti, le RSU maturinganno dopo un anno dalla loro data di assunzione, mentre le RSU del terzo dipendente maturinganno in modo uniforme su tre anni, con un terzo che maturingà annualmente. Questi conferimenti sono stati approvati dal Comitato Compensazioni di Jaguar come incentivo all'accettazione dell'impiego e richiedono un servizio continuato con l'azienda fino alle date di maturazione applicabili.
Jaguar Health (NASDAQ:JAGX) ha anunciado la concesión de unidades de acciones restringidas (RSU) a tres nuevos empleados, efectivas a partir del 8 de enero de 2025. La compañía emitió 15,000 RSU a cada uno de dos empleados y 45,000 RSU a un tercer empleado. Para los dos primeros empleados, las RSU adquiriran derechos después de un año desde sus respectivas fechas de contratación, mientras que las RSU del tercer empleado se adquirirán equitativamente durante tres años, con un tercio adquiriendo derechos anualmente. Estas concesiones fueron aprobadas por el Comité de Compensación de Jaguar como material de inducimiento para la aceptación del empleo y requieren servicio continuo con la empresa hasta las fechas de adquisición aplicables.
재규어 헬스 (NASDAQ:JAGX)는 2025년 1월 8일부터 유효한 제한 주식 단위(RSU)를 세 명의 신규 직원에게 부여한다고 발표했습니다. 회사는 두 명의 직원에게 15,000 RSU씩, 세 번째 직원에게 45,000 RSU를 발행했습니다. 첫 두 명의 직원의 경우, RSU는 각자의 고용 날짜로부터 1년 후에 가득 차며, 세 번째 직원의 RSU는 3년에 걸쳐 균등하게 가득 차고, 매년 1/3씩 가득 차게 됩니다. 이러한 부여는 재규어의 보상위원회에 의해 고용 수용을 위한 유인으로 승인되었으며, 해당 가득 날짜까지 회사에 계속 근무해야 합니다.
Jaguar Health (NASDAQ:JAGX) a annoncé l'octroi d'unités d'actions restreintes (RSU) à trois nouveaux employés, prenant effet à partir du 8 janvier 2025. L'entreprise a émis 15 000 RSU à chacun de deux employés et 45 000 RSU à un troisième employé. Pour les deux premiers employés, les RSU seront acquises sur une durée d'un an à partir de leur date d'embauche, tandis que les RSU du troisième employé seront acquises en parts égales sur trois ans, avec un tiers acquis chaque année. Ces octrois ont été approuvés par le comité de rémunération de Jaguar comme incitation à l'acceptation de l'emploi et nécessitent un service continu au sein de l'entreprise jusqu'aux dates d'acquisition applicables.
Jaguar Health (NASDAQ:JAGX) hat die Gewährung von Restricted Stock Units (RSUs) an drei neue Mitarbeiter bekannt gegeben, die ab dem 8. Januar 2025 wirksam werden. Das Unternehmen hat 15.000 RSUs an zwei Mitarbeiter und 45.000 RSUs an einen dritten Mitarbeiter ausgegeben. Für die ersten beiden Mitarbeiter werden die RSUs nach einem Jahr ab ihren jeweiligen Einstellungsdaten fällig, während die RSUs des dritten Mitarbeiters gleichmäßig über drei Jahre fällig werden, wobei jeweils ein Drittel jährlich fällig wird. Diese Gewährungen wurden vom Vergütungsausschuss von Jaguar als Anreizmaterial für die Annahme der Beschäftigung genehmigt und erfordern eine fortgesetzte Dienstleistung beim Unternehmen bis zu den entsprechenden Fälligkeitsterminen.
- Implementation of employee retention strategy through RSU grants
- Structured vesting schedule promotes long-term employee commitment
- Potential shareholder dilution from new RSU issuance
SAN FRANCISCO, CA / ACCESSWIRE / January 10, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that, effective January 8, 2025, the Company granted 15,000 restricted stock units (RSUs) to New Employee 1, 15,000 RSUs to New Employee 2, and 45,000 RSUs to New Employee 3.
The RSUs for New Employee 1 and New Employee 2 vest over one year starting from each employee's date of hire, and the RSUs for New Employee 3 vest equally over three years, with one-third of the shares vesting each year starting from New Employee 3's date of hire.
The RSUs for all three new employees were granted as an inducement material to each employee's acceptance of employment by the Company and were approved by the Compensation Committee of Jaguar's Board. Vesting of the RSUs is subject to each new employee's continued service with Jaguar through the applicable vesting dates.
About the Jaguar Health Family of Companies
Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Napo's crofelemer is FDA-approved under the brand name Mytesi® for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan and/or rare diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.
For more information about:
Jaguar Health, visit https://jaguar.health
Napo Pharmaceuticals, visit www.napopharma.com
Napo Therapeutics, visit napotherapeutics.com
Magdalena Biosciences, visit magdalenabiosciences.com
Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking statements." In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.
Contact:
Jaguar-JAGX
SOURCE: Jaguar Health, Inc.
View the original press release on accesswire.com
FAQ
How many RSUs did Jaguar Health (JAGX) grant in January 2025?
What is the vesting schedule for JAGX's January 2025 RSU grants?
Why did Jaguar Health (JAGX) issue these RSUs in January 2025?
What conditions are attached to the JAGX RSU grants from January 2025?
